Dr. Reddy’s shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar

Dr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of Keytruda (pembrolizumab), an immunotherapy drug with $29.5 billion in global sales in 2024. The collaboration aims to leverage Alvotech’s R&D strengths and Dr. Reddy’s commercial reach to tap into the fast-growing oncology biosimilars segment and expand global market presence.